GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Financial Strength

Zivo Bioscience (Zivo Bioscience) Financial Strength : 1 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Financial Strength?

Zivo Bioscience has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Zivo Bioscience Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Zivo Bioscience did not have earnings to cover the interest expense. Zivo Bioscience's debt to revenue ratio for the quarter that ended in Mar. 2024 was 5.41. As of today, Zivo Bioscience's Altman Z-Score is -239.81.


Competitive Comparison of Zivo Bioscience's Financial Strength

For the Biotechnology subindustry, Zivo Bioscience's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zivo Bioscience's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Financial Strength distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's Financial Strength falls into.



Zivo Bioscience Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Zivo Bioscience's Interest Expense for the months ended in Mar. 2024 was $-0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-1.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Zivo Bioscience's Interest Coverage for the quarter that ended in Mar. 2024 is

Zivo Bioscience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Zivo Bioscience's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.779 + 0) / 0.144
=5.41

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Zivo Bioscience has a Z-score of -239.81, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -239.81 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zivo Bioscience  (OTCPK:ZIVO) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Zivo Bioscience has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Zivo Bioscience Financial Strength Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Zivo Bioscience (Zivo Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.
Executives
Alison A Cornell director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore officer: CHIEF FINANCIAL OFFICER 4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson director 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne director 9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando officer: Chief Financial Officer C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P 10 percent owner 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp 10 percent owner 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc. 10 percent owner 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc 10 percent owner 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr director 70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox director 470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl officer: President, CEO 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young other: See remarks below. 1800 NW CORPORATE BLVD, BOCA RATON FL 33431